F. Sedarati

发表

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

K. Venkatakrishnan, D. Faller, J. Bolleddula, 2020, Investigational New Drugs.

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

M. Sherman, S. Zeuzem, C. Sarrazin, 2003, Journal of hepatology.

Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon α-2a

S. Zeuzem, C. Sarrazin, F. Sedarati, 2001, Journal of Clinical Microbiology.

Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine

D. Faller, J. Cheong, K. Izutsu, 2022, Journal of Hematology & Oncology.

Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

K. Venkatakrishnan, D. Faller, D. Mould, 2019, British journal of clinical pharmacology.

Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

K. Venkatakrishnan, J. Nemunaitis, D. Faller, 2019, British journal of clinical pharmacology.

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

M. Maris, D. DeAngelo, F. Giles, 2017, Blood Cancer Journal.

Effect of CYP 3 A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours

J. Nemunaitis, D. Faller, Craig A. Lockhart, 2022 .

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

P. Delmas, S. Epstein, C. Recknor, 2009, Clinical therapeutics.

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study

J. Reginster, P. Miller, S. Epstein, 2008, Current medical research and opinion.

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

R. Recker, P. Miller, M. McClung, 2009, Bone.

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

J. Reginster, J. Stakkestad, P. Lakatos, 2008, Clinical Rheumatology.

Two avirulent herpes simplex viruses generate lethal recombinants in vivo.

R. Javier, J. G. Stevens, F. Sedarati, 1986, Science.

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

K. Venkatakrishnan, D. Faller, D. Mahalingam, 2022, Investigational New Drugs.

Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants.

S. Cook, F. Sedarati, J. J. Doucet, 1991, Investigative ophthalmology & visual science.

A latent, nonpathogenic HSV-1-derived vector stably expresses β-galactosidase in mouse neurons

T. Margolis, J. G. Stevens, L. Feldman, 1990, Neuron.

Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial

R. Sudlow, P. Leszczyński, J. Schechtman, 2011 .

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy

J. Reeves, C. Porta, J. Hainsworth, 2022, The oncologist.

Herpes simplex virus latent phase transcription facilitates in vivo reactivation.

R. Javier, E. Wagner, J. G. Stevens, 1990, Virology.

Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome.

T. Margolis, J. G. Stevens, F. Sedarati, 1993, Virology.

Biological basis for virulence of three strains of herpes simplex virus type 1.

J. G. Stevens, F Sedarati, J G Stevens, 1987, The Journal of general virology.

Herpes simplex virus type 1 latency-associated transcription plays no role in establishment or maintenance of a latent infection in murine sensory neurons

K. Izumi, E. Wagner, J. G. Stevens, 1989, Journal of virology.

Pathways of viral gene expression during acute neuronal infection with HSV-1.

T. Margolis, J. G. Stevens, L. Feldman, 1992, Virology.

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.

T. Hassanein, J. Rodés, M. Diago, 2004, Annals of internal medicine.

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

David C. Smith, R. Neuwirth, M. Voss, 2020, British Journal of Cancer.

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

D. Faller, Carrie Lee, A. Lockhart, 2018, Investigational new drugs.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.

D. Faller, W. Tam, M. Maris, 2018, Blood.

Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha.

M. Sherman, G. Marinos, F. Sedarati, 2001, Annals of internal medicine.

Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

M. Maris, D. DeAngelo, S. Blakemore, 2015, British journal of haematology.

Isolation and partial characterization of nucleocapsid forms from cells infected with human cytomegalovirus strains AD169 and Towne.

L. Rosenthal, F. Sedarati, 1988, Intervirology.

A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies

Toshio Shimizu, D. Faller, K. Yonemori, 2021, Targeted Oncology.

Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial

K. Venkatakrishnan, D. Faller, Z. Hua, 2021, Clinical and translational science.

Pathogenesis of a lethal mixed infection in mice with two nonneuroinvasive herpes simplex virus strains

R. Javier, J. G. Stevens, F. Sedarati, 1988, Journal of virology.

Transcription PlaysNo RoleinEstablishment or Maintenance ofa Latent Infection inMurineSensory Neurons

F. Sedarati, 1989 .

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

D. Faller, Carrie Lee, A. Lockhart, 2018, Investigational new drugs.

Concurrent cetuximab, cisplatin, and radiotherapy (RT) for loco-regionally advanced squamous cell carcinoma of the head and neck (SCCHN): Updated results of a novel combined modality paradigm

J. Shah, M. Zelefsky, D. Kraus, 2005 .

Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial

M. Maris, H. Erba, B. Dezube, 2014 .

A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer

R. Wenham, N. Colombo, E. Braicu, 2023, Gynecologic oncology.

Clinical Study Phase 1 study of mTORC 1 / 2 inhibitor sapanisertib ( TAK-228 ) in advanced solid tumours , with an expansion phase in renal , endometrial or bladder cancer

David C. Smith, R. Neuwirth, M. Voss, 2022 .